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Transcriptional regulation-diol-9,10-epoxide (BPDE) is a carcinogen causing bulky-adduct DNA damage. In
this study, we investigated early transcriptional signatures induced by various concentrations (0.005, 0.05,
and 0.5 μM) of this carcinogen in a normal human cell line (FL human amnion epithelial cells) using the
whole-genome Affymetrix HG-U133 Set microarray. The numerous identiﬁed genes were involved in
multiple functions and higher doses of BPDE elicited more robust expression changes. The disturbance of
genes involved in cell cycle regulation, growth and apoptosis was correlated with the S and G2/M phase cell
cycle arrest and cytotoxic phenotypes induced by different levels of BPDE. Bioinformatic analysis showed that
several transcription factors and their related stress signaling pathways might partly account for the
transcriptional signature induced by BPDE. Additionally, gene ontology analysis of the microarray data
showed down-regulation of transport, cytoskeleton and DNA repair by 0.5 μM BPDE exposure. In conclusion,
this genomic analysis helps to understand the mechanism of cellular response to BPDE.
© 2008 Elsevier Inc. All rights reserved.IntroductionPolycyclic aromatic hydrocarbons (PAHs) are widespread environ-
mental pollutants that have been found in cigarette smoke and
charred food, as well as the exhaust from internal combustion engines
and coal-burning factories [1]. Benzo[a]pyrene (BaP) is one of the
most widely studied PAHs. It is metabolized by cytochrome P450 s to
form the ultimate carcinogen, (±)-anti-benzo[a]pyrene-7,8-diol-9,10-
epoxide (BPDE). BPDE can bind covalently to deoxyribonucleic acids
(DNAs) or non-covalently intercalate into double-stranded DNA,
which result in bulky-adduct DNA damage and conformational
abnormalities, respectively [2]. BPDE preferentially reacts with the
N2 position of deoxyguanosine residues to form the dG-N2-BPDE
major adduct, and principally induces a G:C to T:A transversion
mutation [3]. This point mutation is consistently found at the hotspot
codons on the p53 gene in lung cancers from smokers but not from
nonsmokers, thus implicating BPDE as the direct carcinogen account-
ing for cigarette smoking-induced lung cancers [4].
In recent years, genomic tools represented by microarrays have
been implemented into traditional toxicology to form toxicogenomics,
which involves many applications based on gene proﬁles, and in thel-9,10-epoxide; AP-1, activator
ng transcription factor; CREB,
Hangzhou Normal University,
l rights reserved.end helps to understand the complex gene–toxicant interactions. For
instance, gene signatures in exposure to ionizing radiation (IR) [5] and
ultraviolet radiation (UV) [6] have provided insight into mutagenesis
and stress response induced by these classical genotoxic agents,
respectively. Gene proﬁling studies on BPDE have also been performed
in different cell types and treatment models [7–12]. The alteration of
genes involved in p53 pathway, cell cycle, cell growth, apoptosis, DNA
repair, glutathione detoxiﬁcation pathway and inﬂammation etc. have
been identiﬁed, and helps to explain the cell cycle-arrest, mutagenic,
cytotoxic and pro-inﬂammatory effect of BPDE in the related models.
However, the previous mRNA transcriptomic studies on BPDE did not
reach the whole-genome level in their used microarray or rapid
analysis of gene expression (RAGE) technologies. This drawback
impeded obtaining full-scale transcriptional responses induced by
BPDE.
We thus used the whole-genome Affymetrix HG-U133 Set
microarray that covers ∼33,000 human genes and ESTs to explore
responsive genes after exposure to different doses of BPDE in human
amnion epithelial FL cells. We have used FL cell line as an in vitro
model to study low doses of environmental chemical pollutants-
induced responses in normal human cells for the exposure dosage to
them is usually low in human daily life [1,7,13–15]. We performed
genomic analysis at an early 4-h time point after BPDE exposure for
early cellular changes could be useful indicators of the harmful
exposure and help to understand the underlying mechanisms of
chemical-caused damages, also be convenient to compare the BPDE-
induced transcriptional responses with several previously reported
studies being in a similar time-point context [7,8,12]. Through
Affymetrix HG-U133 Set microarray analysis, we have characterized
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0.5 μM) of BPDE. The numerous genes are involved in multiple
functions including cell cycle regulation, proliferation, apoptosis,
transcription, metabolism, transport, cytoskeleton and DNA repair etc.
Gene ontology analysis of the microarray data using GSEA software
has revealed the down-regulation of cell cycle, proliferation, transport,
cytoskeleton and DNA repair by 0.5 μM BPDE exposure. A medium-
throughput quantitative real-time RT-PCR validation based on Taq-
Man® Low-Density Array has conﬁrmed more than one hundred of
gene expression changes. The validated gene sets showed the
correlation between gene expression change and the cell cycle and
cytotoxicity phenotypes induced by different doses of BPDE, also
provided insight into the transcriptional regulation and stress
signaling pathways triggered by BPDE damage.
Results and discussion
Early global changes in gene expression after BPDE treatment
Three concentrations of BPDE (0.005, 0.05, and 0.5 μM) were
used to treat human amnion epithelial FL cells for the microarray
proﬁling study. 0.005 and 0.05 μM BPDE did not affect cell viability
evidently and 0.5 μM BPDE produced a moderate cytotoxicity (88%
cell viability) compared with DMSO vehicle exposure as determined
by MTT reduction assay (Fig. 1). With Affymetrix HG-U133 Set
microarray analysis, we found that the expression of 74, 103, and
2176 probe sets representing 70 (31 up- and 39 down-regulated), 88
(38 up- and 50 down-regulated), and 1707 (307 up- and 1400 down-
regulated) genes were signiﬁcantly altered at 4 h after exposure to
0.005, 0.05, and 0.5 μM BPDE, respectively, compared with the
vehicle exposure (Supplementary Table 1). These proﬁles constituted
a total of 1764 unique genes that were differentially expressed in at
least one of the three concentrations of BPDE treatment. Hierarchical
clustering of the 1764 genes based on their fold changes relative to
the control was performed to visualize the change patterns with the
two biological replicates separated (Fig. 2a). It could be cognized
that the microarray proﬁling replication was acceptable with the
replicate samples clustered most close, and the 0.5 μM BPDE
provoked much more extensive transcriptional changes than the
two lower doses did.
Affymetrix gene ontology annotation showed that the differen-
tially expressed genes were involved in multiple biological functions
such as cell cycle regulation, signal transduction, transcription,
translation, metabolism, transport, cytoskeleton, DNA repair, and
etc. (Supplementary Table 1). We further used Gene Set Enrichment
Analysis (GSEA) software to analyze whether some functional
categories of genes were signiﬁcantly enriched in the differentiallyFig. 1. Cell viability measured by MTT assay. Human amnion epithelial FL cells were
exposed to different concentrations of BPDE for 2 h. At 10 and 22 h after exposure, cell
viability for each treatment was determined based on spectrometry of formazan
formation, and relative viability represented the viability percentage relative to vehicle
exposure. Triplicate experiments were carried out, and x ̄±SD was calculated for
diagram.expressed dataset, and coordinately regulated to enhance or impair
some cellular activities after BPDE treatment. By searching themSigDB
gene ontology gene set collection, GSEA analysis ﬁltered out 233 gene
sets in the 0.5 μM BPDE dataset, 1 gene set in the 0.05 μM BPDE
dataset, and none in the lowest dose dataset. The enriched gene sets in
the 0.5 μM BPDE group were also mainly involved in cell cycle,
proliferation, apoptosis, signal transduction, transcription, RNA
processing, protein metabolism, transport, cytoskeleton, and DNA
repair etc. (Supplementary Table 2). These identiﬁed gene expression
changes prominently indicated down-regulation of cell cycle, pro-
liferation, transport, cytoskeleton, and DNA repair (Supplementary
Fig. 1).
Quantitative real-time RT-PCR validation
A medium-scale quantitative real-time RT-PCR validation of the
microarray results based on TaqMan® Low-Density Array was
performed using independently prepared cell samples. Of 35, 47,
and 234 responsive genes selected from 0.005, 0.05 and 0.5 μM BPDE-
treated samples, 7, 16, and 111 genes showed same change trends in
their expression as that identiﬁed by microarray analysis. Among
which, 2, 6, and 57 genes were conﬁrmed with statistical signiﬁcance
(pb0.05). The validated gene list covers many functional categories,
and includes many genes related with cell cycle regulation, prolifera-
tion, apoptosis, transcription, metabolism, transport, cytoskeleton,
and DNA repair etc. (Table 1 and Fig. 2b).
Dose effect of BDPE on cell cycle regulation
Microarray analysis revealed an early alteration in expression of
numerous cell cycle-regulating genes after BPDE treatment. A portion
of these genes was selected and validated by quantitative RT-PCR
(Table 1). Following 0.05 and 0.5 μM BPDE treatment, the expression
of H1F0 (H1 histone family, member 0), AURKA (aurora kinase A),
CCNB1 (cyclin B1), and CENPA (centromere protein A) was decreased.
The down-regulation of H1F0 implied slow down of DNA synthesis
[16], and the decreased expression of the other three genes that
function in promoting G2/M progression indicated G2/M blockade [17–
19]. Upon 0.5 μM BPDE exposure, the expression of four more genes
was affected, among which three genes that act in promoting G2/M
progression including CDC20 (cell division cycle 20 homolog) [20],
KIF14 (kinesin family member 14) [21], and KIF2C (kinesin family
member 2C) [22] were down-regulated, and one gene that functions
in blocking the onset of mitosis, i.e., PKMYT1 (protein kinase,
membrane-associated tyrosine/threonine 1) [23], was up-regulated.
These gene expression changes indicate that 0.5 μM BPDE induced a
more potently inhibition of G2/M progression compared with 0.05 μM
BPDE treatment. No gene expression changes related to cell cycle
regulation was validated by quantitative RT-PCR in 0.005 μM BPDE-
treated samples.
Flow cytometry assay was performed to explore the correlation
between these gene expression changes and cell cycle phenotype. Cell
cycle distributions were recorded at 4, 13, and 22 h post BPDE
treatment (Fig. 3). 0.05 μM BPDE elicited S phase delay as early as at
4 h post treatment and caused G2/M arrest later as identiﬁed at 13 h
and 22 h post treatment. 0.5 μM BPDE evoked much more severe S
phase delay than 0.05 μM BPDE at all three time points. The S phase-
delayed cells induced by 0.5 μM BPDE were partially released but still
arrested at G2/M transition at 22 h post treatment. The G1 peak
diminished at 22 h after 0.5 μM BPDE treatment, indicating a more
profound S phase and G2/M blockade was triggered compared with
0.05 μM BPDE treatment. The 0.005 μM BPDE seemed to only elicit
much milder G2/M arrest as late as at 13 and 22 h post treatment.
Thus, these data showed the consistency of gene expression change
with cell cycle phenotype and the dose effect of BDPE on the down-
regulation of cell cycle progression.
Fig. 2. (a) Hierarchical clustering analysis. Hierarchical clustering of the 1764 genes that differentially expressed in at least one of the three doses of BPDE treatment was performed
with the two biological replicates separated. Experimental conditions are on the horizontal axis and affected genes are grouped along the vertical axis. Gene expression changes are
colored red for up-regulation or green for down-regulation. The scale of colorbar was ranged from −2 to 2, representing 4-fold change of down and up-regulation, respectively. (b)
Enlargement of two clusters (arrow pointed) in the dendrogram. Among which, a dozen genes involved in cell cycle, proliferation and apoptosis, etc. have been validated by
quantitative RT-PCR.
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kinase inhibitor 1A (p21, Cip1)) and CDKN1C (cyclin-dependent kinase
inhibitor 1C (p57, Kip2)) were induced, and CDK6 (cyclin-dependent
kinase 6) was repressed, which would lead to the impairment of G1/S
transition [24]. However, the simultaneous up-regulation of CCNE1
(cyclin E1) and CCNE2 (cyclin E2) could enhance G1/S transition [24].
Cell cycle analysis showed that a G1/S arrest was not established upon
all three doses of BPDE treatment (Fig. 3).
Responsive genes and related pathways involved in cell growth and
apoptosis
Important genes including membrane receptors, signaling mole-
cules, and transcription factors that determine cell fate were affected
by 0.5 μM BPDE at 4 h post treatment. These included repression of
EGFR (epidermal growth factor receptor) and IGF1R (insulin-likegrowth factor 1 receptor), both of which belong to single-transmem-
brane receptor tyrosine kinases (RTK). Physiological binding of
ligands to these receptors leads to activation of phosphatidylinosi-
tol-3-kinase (PI3K)/Akt, Ras/MAPK (mitogen-activated protein
kinase), and phospholipase C (PLCγ)-mediated pathways, which
regulate a wide variety of downstream targets related with cell
metabolism, migration, proliferation, differentiation, and survival
[25]. Downstream of the PLCγ-mediated pathways were also affected.
PLCγ catalyzes PtdIns(4,5)P2 to generate second messengers includ-
ing diacylglycerol (DAG) and Ins(1,4,5)P3 (IP3). DAG activates protein
kinase C (PKC). IP3 induces Ca2+ release from the calcium pool by
binding to the ion channel receptor ITPR1 (inositol 1,4,5-triphosphate
receptor type 1)/IP3R. The released Ca2+ binds with calmodulin,
thereby activating Ca2+/calmodulin-dependent protein kinases
(CaMKs) [25]. Upon 0.5 μM BPDE treatment, the expression of PRKCA
(protein kinase C, alpha) and ITPR1 were reduced. Thus, the down-
Table 1
Validation of gene expression changes at 4 h post BPDE treatment with quantitative real-time RT-PCR
RefSeq ID Probe ID Gene title Gene
symbol
Fold change
Array PCR
0.005 μM BPDE
Regulation of transcription
NM_153207 225889_at AE binding protein 2 AEBP2 −1.34 −1.35
NM_001271 228999_at Chromodomain helicase DNA binding protein 2 CHD2 −1.78 −1.28
Signal transduction
NM_016441 228496_s_at Cysteine rich transmembrane BMP regulator 1 (chordin-like) CRIM1 −1.23 −1.20
NM_001901 209101_at Connective tissue growth factor CTGF −1.33 −1.20
NM_139072 226281_at Delta/notch-like EGF repeat containing DNER −1.46 −1.35⁎
Membrane trafﬁcking
NM_001283 205196_s_at Adaptor-related protein complex 1, sigma 1 subunit AP1S1 −1.52 −1.29⁎
Solute transport
NM_016612 221920_s_at Solute carrier family 25, member 37 SLC25A37 1.95 1.21
0.05 μM BPDE
Regulation of transcription
NM_006305 201043_s_at Acidic (leucine-rich) nuclear phosphoprotein 32 family, member A ANP32A −1.23 −1.71
NM_001913 214743_at Cut-like homeobox 1 CUX1 −1.52 −1.62
Cell cycle regulation
NM_003600 208079_s_at Aurora kinase A AURKA −1.50 −1.70
NM_031966 228729_at Cyclin B1 CCNB1 −1.36 −1.87⁎
NM_001809 204962_s_at Centromere protein A CENPA −1.48 −3.21
NM_005318 208886_at H1 histone family, member 0 H1F0 −1.89 −1.98
Signal transduction
NM_016441 228496_s_at Cysteine rich transmembrane BMP regulator 1 (chordin-like) CRIM1 −1.32 −1.35
NM_001901 209101_at Connective tissue growth factor CTGF −1.62 −1.59⁎
NM_001554 201289_at Cysteine-rich, angiogenic inducer, 61 CYR61 −1.26 −1.41
NM_139072 226281_at Delta/notch-like EGF repeat containing DNER −1.28 −1.45⁎
Protein folding
NM_014260 233588_x_at Prefoldin subunit 6 PFDN6 −1.40 −1.93
Membrane trafﬁcking
NM_001283 205196_s_at Adaptor-related protein complex 1, sigma 1 subunit AP1S1 −1.58 −1.52⁎
NM_014914 204066_s_at ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 AGAP1 −1.39 −1.90⁎
Unknown
NM_001620 235281_x_at AHNAK nucleoprotein AHNAK −1.57 −1.48
NM_030919 225687_at Family with sequence similarity 83, member D FAM83D −1.40 −2.39⁎
NM_018386 225149_at PCI domain containing 2 PCID2 −1.34 −1.35
0.5 μM BPDE
Regulation of transcription
NM_153207 225889_at AE binding protein 2 AEBP2 −4.13 −1.24⁎
NM_020731 229354_at Aryl-hydrocarbon receptor repressor AHRR −2.01 −3.00
NM_013275 238538_at Ankyrin repeat domain 11 ANKRD11 −3.45 −1.74⁎
NM_001674 202672_s_at Activating transcription factor 3 ATF3 2.39 1.67⁎
NM_004824 203098_at Chromodomain protein, Y-like CDYL −4.35 −1.27⁎⁎
NM_001913 214743_at Cut-like homeobox 1 CUX1 −2.41 −2.10⁎⁎
NM_006460 202814_s_at Hexamethylene bis-acetamide inducible 1 HEXIM1 2.58 1.96
NM_002398 204069_at Meis homeobox 1 MEIS1 −2.75 −2.06⁎
NM_002467 202431_s_at v-myc myelocytomatosis viral oncogene homolog (avian) MYC −1.64 −1.31
NM_002518 205460_at Neuronal PAS domain protein 2 NPAS2 −2.13 −1.66
NM_003298 225477_s_at Nuclear receptor subfamily 2, group C, member 2 NR2C2 −3.23 −1.27
NM_005870 208740_at Sin3A-associated protein, 18 kDa SAP18 2.02 1.61
NM_021961 214600_at TEA domain family member 1 (SV40 transcriptional enhancer factor) TEAD1 −2.75 −1.80
NM_014943 203556_at Zinc ﬁngers and homeoboxes 2 ZHX2 −11.06 −1.76⁎
Cell cycle regulation
NM_003600 204092_s_at Aurora kinase A AURKA −2.78 −3.31⁎
NM_031966 214710_s_at Cyclin B1 CCNB1 −1.64 −1.64⁎
NM_001238 213523_at Cyclin E1 CCNE1 1.86 1.59⁎
NM_057735 205034_at Cyclin E2 CCNE2 1.67 2.18⁎
NM_001255 202870_s_at Cell division cycle 20 homolog (S. cerevisiae) CDC20 −1.71 −1.65⁎
NM_001259 207143_at Cyclin-dependent kinase 6 CDK6 −2.93 −1.55⁎
NM_000389 202284_s_at Cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 1.81 1.36
NM_000076 213182_x_at Cyclin-dependent kinase inhibitor 1C (p57, Kip2) CDKN1C 1.46 1.23
NM_001809 204962_s_at Centromere protein A CENPA −3.95 −2.23⁎⁎
NM_005318 208886_at H1 histone family, member 0 H1F0 −2.37 −2.04⁎
NM_014875 206364_at Kinesin family member 14 KIF14 −3.01 −1.49
(continued on next page)i
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Table 1 (continued)
RefSeq ID Probe ID Gene title Gene
symbol
Fold change
Array PCR
0.5 μM BPDE
Cell cycle regulation
NM_006845 211519_s_at Kinesin family member 2C KIF2C −1.60 −1.55⁎
NM_014572 227013_at LATS, large tumor suppressor, homolog 2 (Drosophila) LATS2 −3.05 −1.80⁎
NM_003550 204857_at MAD1 mitotic arrest deﬁcient-like 1 (yeast) MAD1L1 −2.04 −1.90
NM_004203 204267_x_at Protein kinase, membrane associated tyrosine/threonine 1 PKMYT1 1.72 1.70⁎
Signal transduction
NM_006738 221718_s_at A kinase (PRKA) anchor protein 13 AKAP13 −4.97 −2.61⁎
NM_173075 213419_at Amyloid beta (A4) precursor protein-binding, family B,
member 2 (Fe65-like)
APBB2 −18.60 −3.03⁎
NM_006888 200653_s_at Calmodulin 1 (phosphorylase kinase, delta) CALM1 1.25 1.31
NM_016441 202551_s_at Cysteine rich transmembrane BMP regulator 1 (chordin-like) CRIM1 −2.08 −1.55⁎⁎
NM_001554 201289_at Cysteine-rich, angiogenic inducer, 61 CYR61 −1.91 −1.29⁎
NM_004087 202514_at Discs, large homolog 1 (Drosophila) DLG1 −2.99 −1.33
NM_005228 201983_s_at Epidermal growth factor receptor (erythroblastic leukemia
viral (v-erb-b) oncogene homolog, avian)
EGFR −2.61 −2.05⁎
NM_004864 221577_x_at Growth differentiation factor 15 GDF15 3.41 2.45⁎
NM_001945 203821_at Heparin-binding EGF-like growth factor HBEGF 3.14 1.25⁎
NM_000875 203627_at Insulin-like growth factor 1 receptor IGF1R −3.16 −2.10⁎
NM_002222 203710_at Inositol 1,4,5-triphosphate receptor, type 1 ITPR1 −2.62 −1.92⁎
NM_005923 203836_s_at Mitogen-activated protein kinase kinase kinase 5 MAP3K5 −3.67 −1.50
NM_003791 201620_at Membrane-bound transcription factor peptidase, site 1 MBTPS1 −1.67 −1.50⁎⁎
NM_145117 218330_s_at Neuron navigator 2 NAV2 −3.75 −2.49⁎
NM_014840 204589_at NUAK family, SNF1-like kinase, 1 NUAK1 −3.32 −1.39
NM_002581 224940_s_at Pregnancy-associated plasma protein A, pappalysin 1 PAPPA −4.06 −1.68⁎
NM_000921 206389_s_at Phosphodiesterase 3A, cGMP-inhibited PDE3A −3.95 −1.72
NM_006457 203242_s_at PDZ and LIM domain 5 PDLIM5 −3.38 −1.83
NM_003768 200788_s_at Phosphoprotein enriched in astrocytes 15 PEA15 1.56 1.60
NM_025179 213030_s_at Plexin A2 PLXNA2 −3.27 −2.11
NM_002737 215195_at Protein kinase C, alpha PRKCA −2.92 −2.17⁎
NM_004249 209084_s_at RAB28, member RAS oncogene family RAB28 −1.97 −1.45
NM_032730 224509_s_at Reticulon 4 interacting protein 1 RTN4IP1 −5.13 −1.44⁎
NM_003246 201108_s_at Thrombospondin 1 THBS1 −1.69 −1.51
NM_007118 208178_x_at Triple functional domain (PTPRF interacting) TRIO −3.21 −1.87
NM_003371 205537_s_at Vav 2 guanine nucleotide exchange factor VAV2 −8.18 −2.52⁎
Metabolism
NM_014324 209425_at Alpha-methylacyl-CoA racemase AMACR 1.54 1.81⁎
NM_024830 201818_at Lysophosphatidylcholine acyltransferase 1 LPCAT1 −7.50 −1.17⁎
NM_000104 202434_s_at Cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 2.95 1.57⁎
NM_020474 201722_s_at UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 1 (GalNAc-T1)
GALNT1 −1.81 −1.46
NM_017423 218313_s_at UDP-N-acetyl-alpha-D-galactosamine:polypeptide
N-acetylgalactosaminyltransferase 7 (GalNAc-T7)
GALNT7 −2.08 −1.28⁎
NM_147175 230030_at Heparan sulfate 6-O-sulfotransferase 2 HS6ST2 −2.91 −1.86
NM_015440 225520_at Methylenetetrahydrofolate dehydrogenase
(NADP+ dependent) 1-like
MTHFD1L −2.76 −1.84
NM_000434 208926_at Sialidase 1 (lysosomal sialidase) NEU1 1.73 1.61⁎⁎
NM_020376 212705_x_at Patatin-like phospholipase domain containing 2 PNPLA2 1.57 1.28
NM_002970 203455_s_at Spermidine/spermine N1-acetyltransferase 1 SAT1 2.94 1.68
NM_024636 220187_at STEAP family member 4 STEAP4 −1.74 −1.12
DNA replication
NM_002897 203748_x_at RNA binding motif, single stranded interacting protein 1 RBMS1 −3.28 −1.71
DNA repair
NM_002874 223598_at RAD23 homolog B (S. cerevisiae) RAD23B −2.15 −1.53⁎
RNA processing
NM_005463 209067_s_at Heterogeneous nuclear ribonucleoprotein D-like HNRPDL −2.13 −1.59
NM_006362 208922_s_at Nuclear RNA export factor 1 NXF1 1.75 1.98
NM_006275 208804_s_at Splicing factor, arginine/serine-rich 6 SFRS6 1.62 1.30
Protein synthesis
NM_003750 200596_s_at Eukaryotic translation initiation factor 3, subunit A EIF3A −1.86 −1.10
NM_002094 215438_x_at G1 to S phase transition 1 GSPT1 −1.65 −1.61⁎
Protein catabolism
NM_031483 239101_at Itchy homolog E3 ubiquitin protein ligase (mouse) ITCH −10.07 −1.53
NM_174916 226921_at Ubiquitin protein ligase E3 component n-recognin 1 UBR1 −3.33 −1.34
Cytoskeleton
NM_020806 220773_s_at Gephyrin GPHN −1.98 −2.73⁎
NM_005573 203276_at Lamin B1 LMNB1 −4.17 −1.37
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Table 1 (continued)
RefSeq ID Probe ID Gene title Gene
symbol
Fold change
Array PCR
0.5 μM BPDE
Cytoskeleton
NM_022818 208785_s_at Microtubule-associated protein 1 light chain 3 beta MAP1LC3B 1.38 1.32
NM_023009 200644_at MARCKS-like 1 MARCKSL1 2.85 1.70
NM_001069 204141_at Tubulin, beta 2A TUBB2A 2.53 1.63
Membrane trafﬁcking
NM_001283 205196_s_at Adaptor-related protein complex 1, sigma 1 subunit AP1S1 −1.59 −1.17
NM_014914 204066_s_at ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 AGAP1 −3.94 −2.99⁎⁎
NM_003024 209297_at intersectin 1 (SH3 domain protein) ITSN1 −2.70 −1.56⁎
Solute transport
NM_004694 207038_at Solute carrier family 16, member 6 (monocarboxylic acid transporter 7) SLC16A6 −1.99 −1.30
NM_052885 227176_at Solute carrier family 2 (facilitated glucose transporter), member 13 SLC2A13 −3.08 −1.38
Immune response
NM_005516 200904_at Major histocompatibility complex, class I, E HLA-E 1.61 1.45⁎
NM_003811 206907_at Tumor necrosis factor (ligand) superfamily, member 9 TNFSF9 1.51 1.71⁎
NM_025217 238542_at UL16 binding protein 2 ULBP2 1.49 2.30⁎
Unknown
NM_007011 63825_at Abhydrolase domain containing 2 ABHD2 −1.81 −1.50⁎
NM_019004 224682_at Ankyrin repeat and IBR domain containing 1 ANKIB1 −2.26 −1.60⁎
NM_031450 221534_at Chromosome 11 open reading frame 68 C11orf68 2.04 1.21
NM_138425 224719_s_at Chromosome 12 open reading frame 57 C12orf57 1.67 1.38
NM_033286 225300_at Chromosome 15 open reading frame 23 C15orf23 −2.66 −1.73⁎⁎
NM_020317 209006_s_at Chromosome 1 open reading frame 63 C1orf63 3.66 1.51
XR_017929 230251_at Chromosome 6 open reading frame 176 C6orf176 −4.55 −2.08⁎
NM_152515 229610_at Cytoskeleton associated protein 2-like CKAP2L −2.31 −1.60
NM_017993 219501_at Ecto-NOX disulﬁde-thiol exchanger 1 ENOX1 −2.55 −3.38⁎⁎
NM_153690 227410_at Family with sequence similarity 43, member A FAM43A 1.84 1.50⁎
NM_016605 218023_s_at Family with sequence similarity 53, member C FAM53C 2.51 1.64⁎
NM_030919 225687_at Family with sequence similarity 83, member D FAM83D −2.27 −1.72⁎
NM_022763 218618_s_at Fibronectin type III domain containing 3B FNDC3B −4.77 −2.38⁎⁎
NM_017640 230793_at Leucine rich repeat containing 16A LRRC16A −2.54 −1.98⁎
NM_019606 219798_s_at Methylphosphate capping enzyme MEPCE 1.38 1.38
NM_007211 225946_at Ras association (RalGDS/AF-6) domain family 8 RASSF8 −3.10 −1.24⁎
NM_006997 202289_s_at Transforming, acidic coiled-coil containing protein 2 TACC2 −3.88 −1.48
NM_020147 219596_at THAP domain containing 10 THAP10 1.68 1.37
NM_032021 223595_at Transmembrane protein 133 TMEM133 −9.66 −2.01
NM_031442 209656_s_at Transmembrane protein 47 TMEM47 1.47 1.59
NM_032883 228737_at TOX high mobility group box family member 2 TOX2 −3.15 −1.50
NM_015285 212880_at WD repeat domain 7 WDR7 −6.12 −1.72
NM_016061 217783_s_at Yippee-like 5 (Drosophila) YPEL5 1.38 1.15
“⁎” and “⁎⁎” represent pb0.05 and b0.01, respectively, compared with vehicle treatment (Student's paired, two-tailed t-test analysis).
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negative effect on cell growth.
Two important signaling genes, GDF15 (growth differentiation
factor 15) and PEA15 (phosphoprotein enriched in astrocytes 15), were
up-regulated upon 0.5 μM BPDE treatment. GDF15 is a member of the
TGF-beta superfamily, and induced by many stress stimuli including
DNA damage [5]. Its expression was correlated with increased
apoptosis in some cell types [26]. PEA15 encodes a protein character-
ized with an ERK1/2 binding domain and a nuclear export sequence
[27]. It can repress ERK1/2 activity by sequestration of ERK1/2 at
cytoplasm, thus decreased ERK1/2-dependent transcription and
slowed down cell proliferation. The altered expression of these two
genes induced by BPDE would disturb cell proliferation and apoptosis.
The expression of many transcription regulators (TFs) was altered
upon 0.5 μM BPDE treatment (Table 1). Among which included up-
regulation of ATF3 (activating transcription factor 3) and HEXIM1
(hexamethylene bis-acetamide inducible 1), and down-regulation of
MYC (v-myc myelocytomatosis viral oncogene homolog (avian)).
ATF3 is induced by a wide variety of stress signals, and its induction
is correlated with cellular injury [28]. Over-expression of ATF3 often
leads to detrimental consequences [28]. The HEXIM1 protein, in
associationwith 7SK snRNA, binds and inhibits the kinase activity of P-TEFb (CDK9/CyclinT). P-TEFb activity is crucial for efﬁcient RNA
polymerase II-dependent transcription elongation. Up-regulation of
HEXIM1 mRNA and protein is a program for differentiation, and can
cause growth inhibition in several cell types [29]. The MYC
oncoprotein regulates numerous target genes involved in cell cycle,
metabolism, protein synthesis, cell growth, and apoptosis [30].
Deregulation of this gene was associated with cellular apoptosis
[31]. Thus, the alteration of these genes might affect cell growth,
proliferation, differentiation, and apoptosis.
The metabolism gene SAT1 (spermidine/spermine N1-acetyltrans-
ferase 1) was up-regulated upon 0.5 μM BPDE treatment (Table 1).
SAT1 encodes a rate-limiting enzyme in polyamine catabolism.
Reduction of polyamine level by SAT1 was shown to promote
apoptosis and inhibit cell growth [32]. Its up-regulation by BPDE
treatment possibly indicated a tendency of apoptosis and growth
suppression.
These data demonstrate that 0.5 μM BPDE had profound impacts
on many aspects of the cellular processes through regulating gene
expression and related signal transduction. The overall effects of BPDE
were to down-regulate the cell growth and activate apoptosis at early
stage although MTT assay showed the cellular viability was only
moderately affected.
Fig. 3. Cell cycle analysis. Human amnion epithelial FL cells were exposed to various concentrations of BPDE for 2 h. At 4, 13 and 22 h post exposure, cells were collected, ﬁxed, stained
with propidium iodide, and acquired on a Coulter EPICS XL ﬂow cytometer. Triplicate experiments were carried out, and one of which was displayed as a representative. For each cell
cycle proﬁle graph, the x axis represented FL3-PI ﬂuorescence value that maximized at 1024 channels, and the y axis represented cell counts that maximized at 512.
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signaling pathways
Analysis of the promoters of the affected genes would help to
predict corresponding TFs with changes in both expression levels
and activities and their related signaling pathways. 36 up-regulatedTable 2
Prediction of transcription factors activated by 0.5 μM BPDE treatmenta
Gene Symbol Fold change Predicted tra
Array PCR
ATF3 2.39 1.67⁎ ATF4, AP-1, F
CDKN1A 1.81 1.36 AP-1, TP53, A
CDKN1C 1.46 1.23 ATF6, ELK1
PKMYT1 1.72 1.70⁎ ATF4, AP-1
CALM1 1.25 1.31 AP-1, ATF2, F
GDF15 3.41 2.45⁎ TP53, NFKB1
HBEGF 3.14 1.25⁎ AP-1, ATF4, F
PEA15 1.56 1.60 NFKB1, TP53
CYP1B1 2.95 1.57⁎ CREB1
NEU1 1.73 1.61⁎⁎ FOS
PNPLA2 1.57 1.28 ATF6, ATF2:J
SAT1 2.94 1.68 ATF2
NXF1 1.75 1.98 ATF4
SFRS6 1.62 1.30 ATF-1, ATF3
MAP1LC3B 1.38 1.32 CREB1
MARCKSL1 2.85 1.70 CREB1, NF-k
TUBB2A 2.53 1.63 CREB1, AP-1
TNFSF9 1.51 1.71⁎ NFKB1, Chop
C11orf68 2.04 1.21 ATF4, CREB1
C12orf57 1.67 1.38 ELK1, ATF6
FAM43A 1.84 1.50⁎ RELA, REL, F
THAP10 1.68 1.37 ATF3
TMEM47 1.47 1.59 CREB1, ATF2
YPEL5 1.38 1.15 CREB1, AP-1
a The Promoter Analysis Pipeline web application suite was used to identify regulatory tra
related to stress response were displayed in order of their prediction probability from left t
treatment (Student's paired, two-tailed t-test analysis).genes in response to 0.5 μM BPDE were validated with quantitative
RT-PCR (Table 1). By computer-assisted prediction, TFs known to be
downstream of various stress signaling pathways were picked out,
thereby generated stress response-enriched TF proﬁles for 24 up-
regulated genes (Table 2). The prominent transactivators for these
affected genes were the AP-1 family TFs (AP-1, FOS and ATF2: JUNnscription factors Gene function
OS, REL Transcription factor
TF3 Cell cycle arrest, inhibit G1/S transition
Cell cycle arrest, inhibit G1/S transition
Cell cycle arrest, inhibit G2/M transition
OS, ELK1 Calmodulin
TGFβ family member
OS Growth factor
Sequestration of ERKs at cytoplasm
Xenobiotic and lipid metabolism
Cleavage of terminal sialic acid residues
UN, CREB1, ATF3, ELK1, TP53 Lipid metabolism
Amino acid metabolism
RNA export from nucleus
RNA splicing
Microtubule assembly
appaB Actin cytoskeleton dynamics
, ATF2:JUN Constituent of cytoskeleton
-cEBP Immune response
, NFKB1 Unknown
Unknown
OS Unknown
Unknown
, ATF4 Unknown
, ELK1, ATF4 Unknown
nscription factors for up-regulated genes induced by 0.5 μM BPDE. Those transactivators
o right. The “⁎” and “⁎⁎” denote pb0.05 and b0.01, respectively, compared with vehicle
339X. Lu et al. / Genomics 93 (2009) 332–342heterodimer), the ATF/CREB family members (CREB1, ATF4, ATF6 and
ATF3), NF-κB with its subunits (NFKB1, RELA and REL), TP53, and
ELK1.
Among these predicted TFs, previous studies had conﬁrmed that
AP-1, ATF3, NF-κB, TP53, and ELK1 could be activated by BPDE in various
cell types [12,33–35]. The upstream signaling pathways for activation
of these TFs were the MAPKs (ERKs, JNKs, p38) pathways for activating
AP-1, the JNK/SAPK pathway for ATF3 accumulation and activation, the
phosphorylation and degradation of IκBα for stimulating NF-κB, the
ATM/ATR, ERKs, and p38 MAPKs for activating TP53, and the ERKs
pathway for activating ELK1. The targeted genes included CDKN1A,
CDKN1C, PKMYT1, ATF3, SAT1, GDF15, PEA15, and etc. (Table 2). As
mentioned above, the up-regulation of these genes would impede cell
cycle progression, inhibit cell growth, and promote apoptosis.
The predicted activation of ATF/CREB family members (such as
CREB1, ATF4, and ATF6) by BPDE has not been reported before. CREB1
is a phosphorylation-dependent TF that can be activated by MAPKs,
CaMKs, Akt, and protein kinase A (PKA) [36]. Four up-regulated genes
upon 0.5 μM BPDE treatment were predicted to be targeted by CREB1
regulators, including three cytoskeleton-related genes, i.e. MARCKSL1
(MARCKS-like) [37], MAP1LC3B (microtubule-associated protein 1
light chain 3 beta) [38], and TUBB2A (tubulin, beta 2A) [39], and one
metabolism gene, i.e. CYP1B1 (cytochrome P450, family 1, subfamily B,
polypeptide 1). These cytoskeleton-related genes were not known
involved in cellular response to BPDE exposure before. CYP1B1 is an
enzyme involved in metabolizing procarcinogens including polycyclic
aromatic hydrocarbons [40]. The induction of CYP1B1 by benzo[a]
pyrene (BaP) was well-known [40], and BPDE is one of the ultimate
carcinogens of BaP.
Both ATF4 and ATF6 were known involved in endoplasmic reticulum
(ER) stress [41]. Following the initiation of ER stress, ATF4 is trans-
lationally activated by EIF2AK3 (PERK) kinase-mediated phosphoryla-
tion of eukaryotic initiation factor 2 alpha (eIF2α), while ATF6 is post-
translationally capacitated following sequential cleavage by MBTPS1
(membrane-bound transcription factor peptidase, site 1) and MBTPS2.
After activation, ATF4 regulates the expression of genes involved in oxi-
dative stress resistance, and ATF6 enhances the production of molecular
chaperons such as HSPA5 (GRP78/BiP), HERPUD1 (Herp), and DNAJC3
(P58IPK), therebymediatingprotective roles for cells. BothTFs also induce
the expression of the pro-apoptotic protein DDIT3 (GADD153/CHOP).
Our lab previously found that the protein level of HSPA5 and DDIT3 was
up-regulated upon BPDE treatment [13]. These evidences support that
BPDE may trigger ER stress response, in which ATF4 and ATF6 are
involved. In this study, we found that several ATF4- and ATF6- targeted
genes, such as ATF3, PKMYT1, CDKN1C, and etc. were activated in
response to BPDE treatment,which could lead to down-regulation of cell
cycle and cell growth (Table 2). Furthermore, we previously showed that
another DNA-damaging alkylating agent, N-methyl-N′-nitro-N-nitroso-
guanidine (MNNG), could activate a cAMP-PKA-CREB signaling pathway
invero cells [42] andER stress in FL cells [14], implying that the activation
ofATF/CREBTFs andER stress could be a commonmechanismof cellular
response to chemical genotoxic agents.
In this study, we have investigated genome-wide transcriptional
response by DNA microarray at an early stage after exposure to
different levels of the mutagen and carcinogen BPDE in human
amnion epithelial FL cells. More than a hundred of gene expression
changes were validated with quantitative real-time RT-PCR. These
early responsive genes belong to multiple functional categories. The
0.5 μM BPDE elicited much more extensive transcriptional changes
compared with 0.05 and 0.005 μM BPDE. Also the 0.05 μM BPDE
elicited more changes in gene expression than the 0.005 μMdose such
as in cell cycle genes. In correlation, the high-dose BPDE generated
moderate cytotoxicity and provoked severe S and G2/M phase cell
cycle arrest, while the two lower doses did not impair cell viability
evidently, but the medium dose still evoked apparent S and G2/M
phase cell cycle arrest in contrast to the low dose. Previously, Akermanet al. showed a high-dose (1 μM) BPDE that resulted in more than 50%
cytotoxicity within 24 h induced tens of transcriptional changes in TK6
cells of several hundred genes spotted on a cDNA array, while two
lower doses (0.1 and 0.01 μM) of BPDE with low cytotoxicity almost
did not induce any transcriptional changes of these genes, though
both of which also induced adducts and mutation [7]. These
observations regarding cellular differential response to various levels
of BPDE indicate that gene expression and phenotypic changes are
tightly linked, and higher doses of toxicants would have deeper
impact on both of which.
Cell division cycle is a highly coordinated machinery accompanied
by complex transcriptional programs, which involve periodical
expression of nearly one thousand genes (N850) according to the
cell cycle phases [43]. A prominent observation of this study is that the
expression of more than 150 of these cell cycle phase-related genes
was modulated, and adapted to the cell cycle arrest phenotype after
BPDE exposure (Table 1 and Supplementary Table 1). For example,
histone genes are highly expressed in S phase under normal
conditions [43], which implies that a naturally growing culture with
more S phase cells in proportion would have higher expression of
these genes. However, the expression of H1F0 histone gene was less in
0.05 and 0.5 μM BPDE-treated cultures than control culture, though
there were higher proportions of S phase cells in treated cultures.
This down-regulation most likely accommodated with the S phase
arrest induced by BPDE. A number of other genes such as that function
in G2/M phase were also regulated at early stage and adapted to the
cell cycle arrest as described before. Other labs have also observed
that expression of a few cell cycle genes including histone genes and
cyclin genes were altered by BPDE damage and correlated with S and
G2/M phase arrest in different treatment and cell models [7,10–12].
Thus, disturbance of the periodically expressed cell cycle genes might
be a common mechanism when establishing cell cycle arrest upon
DNA damage.
BPDE was previously shown not to induce a G1/S transition arrest
in both normal and transformed cell types [10,12,44], as also found in a
normal cell type in this study. Such a nature would presumably
promote mutagenesis and genome instability due to permitting DNA
synthesis on damaged templates [44]. An important ﬁnding in this
study was that the expression of CCNE1 and CCNE2 was up-regulated
upon 0.5 μM BPDE treatment. This modulation would overcome the
negative effect of altered expression of CDK6, CDKN1A and CDKN1C,
and promote the damaged cells entry into S phase. Thus, CCNE1 and
CCNE2 may play a role in the G1-arrest deﬁciency, and act as
oncogenes in BPDE-induced mutagenesis and carcinogenesis.
Abundant genes related to cell growth and apoptosis were affected
by the 0.5 μMBPDE treatment, e.g., the up-regulation of GDF15, PEA15,
ATF3, HEXIM1 and SAT1, and the down-regulation of EGFR, IGF1R,
PRKCA, ITPR1 and MYC, which generally indicated cellular damage,
growth inhibition, and apoptotic tendency. The up-regulation of ATF3
[8,12], HEXIM1 [11] and SAT1 [7], and down-regulation ofMYC [7], had
also been found in previous studies, indicating common mechanisms
can exist in response to BPDE in different cell types.
Bioinformatic analysis of up-regulated genes has predicted the
activation of stress response-related TFs including AP-1, ATF3, NF-κB,
TP53, ELK1, CREB1, ATF4, ATF6, and etc. after BPDE exposure. Among
which, activation of AP-1, ATF3, NF-κB, TP53 and ELK1 as well as
related stress signaling pathways, e.g. MAPKs (ERKs, JNKs, and p38
MAPK), NF-κB, and ATM/ATR, by BPDE was previously reported
[12,33–35], while the predicted activation of CREB1, ATF4, and ATF6
by BPDE, and its possible relation with ER stress pathway were not
known before. The up-regulated genes were implicated in multiple
functions including cell cycle, cell survival, signal transduction, RNA
processing, cytoskeleton and metabolism, etc. These transcriptional
changes and cross-talks among their related signaling pathways
reﬂected the complexity of gene regulation in cellular response to
chemical insults.
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identiﬁed the enrichment of genes implicated in cell cycle regulation,
proliferation, apoptosis, signal transduction, transcription, RNA proces-
sing, protein metabolism, transport, cytoskeleton and DNA repair etc.
(Supplementary Table 2). The alteration of these genes primarily
indicated down-regulation of cell cycle, proliferation, transport,
cytoskeleton and DNA repair after 0.5 μM BPDE exposure (Supplemen-
tary Fig. 1). In addition to above-mentioned quantitative RT-PCR-
validated genes, other enriched gene categories identiﬁed by micro-
array may also have important relevance with cellular response to
BPDE. Many cytoskeleton genes were also involved in cell cycle G2/M
phase, e.g., KIF2C, KIF11, CENPF, MID1, TPX2, BUB1, and etc. [43],
indicating that down-regulation of cytoskeleton might be related to
the cell cycle arrest induced by BPDE. The repression of transport genes
such as AP1S1, AP1G1, AGAP1, EEA1, KPNA1, KPNA3, KPNA6, KPNB1, and
etc., which played roles in vesicle-mediated and nucleocytoplasmic
transport [45,46], was previously not noticed. The down-regulation of
DNA repair genes such as RAD23B, GTF2H1, GTF2H4, RAD50, RAD51C,
TDG, and etc. that function in nucleotide excision repair, homologous
recombination or base excision repair [47], would possibly promote
mutagenesis after BPDE-DNAdamage [11]. All these expression changes
and related biological meanings deserve further investigations.
In summary, this study revealed that BPDE exposure could induce
early transcriptional changes and disturb multiple cellular processes,
which parallel with cell cycle arrest and growth inhibition in a dose-
dependent manner. Analysis of the function and regulation of the
affected genes helped to understand how stress signaling pathways,
transcription factors, and their target genes were coordinated in the
cellular response to BPDE at early stage. The gene expression change
levels induced by the dosage of BPDE used in this studywere relatively
low, and independent RNA samples were applied for the DNA
microarray and real-time RT-PCR measurements, both of which may
account for why only a part of differentially expressed genes observed
by the microarray analysis was veriﬁed by the RT-PCR measurements.
Further biological experiments are needed to elucidate what exact
roles these differentially expressed genes and related pathways play in
this chemical-induced effect. In addition, more meticulous analysis of
gene expression patterns in a variety of cell types, and time-course
comparison will help to generate a general model for cellular
responses to genotoxic stress.
Materials and methods
Cell culture and chemical treatment
Benzo[a]pyrene diol epoxide ((±)-anti-BPDE) was obtained from
the National Cancer Institute Chemical Carcinogen Reference Standard
Repository (Kansas City, MO). BPDE stock solution was prepared in
anhydrous dimethyl sulfoxide (DMSO) and used immediately. Human
amnion epithelial FL cells were cultured in minimal essential medium
(MEM, Gibco-Invitrogen, Carlsbad, CA) supplemented with 10%
newborn bovine serum (Gibco-Invitrogen), 100 U/mL penicillin, and
100 μg/mL streptomycin in a humidiﬁed atmosphere of 5% CO2 at
37 °C. For treatment, FL cells in logarithmic growth were exposed to
various doses of BPDE or a DMSO solvent control in serum-free
medium for 2 h. All cultures received an equal volume of DMSO (0.1%).
Following the chemical exposure, the cultures were rinsed with
Hank's buffer solution, and incubated in fresh serum-supplemented
medium for additional time before harvest. The cytotoxicity of BPDE
was determined with a MTT reduction assay using CellTiter 96®
AQueous One Solution Cell Proliferation Assay Kit (Promega).
Microarray proﬁling and data analysis
For microarray study, duplicate cultures were treated with various
concentrations (0, 0.005, 0.05, 0.5 μM) of BPDE for 2 h, respectively. At4 h post treatment, cells were rinsed once with ice-cold phosphate
buffered saline and lysed, total RNA was isolated with Trizol reagents
(Invitrogen), and further puriﬁed using the RNeasy Mini Kit (Qiagen,
Valencia, CA). The quality and quantity of RNA were assessed by
denaturing agarose gel electrophoresis and spectrophotometric ultra-
violet absorbance at 260/280 nm, respectively. Each of the generated
RNA samples was measured by one Human Genome U133 Set array,
which covers more than 39,000 transcripts and variants representing
33,000 well-substantiated human genes and expressed sequence tags.
Microarray hybridization and detection was performed as described in
the Affymetrix GeneChip Expression Analysis Technical Manual.
Microarray data analysis was performed according to the Affyme-
trix GeneChip® Expression Analysis (Data Analysis Fundamentals).
The probe level data was processed using the MAS5.0 algorithm, and
the average intensity of each array was globally scaled to a target of
500. The followed single-array and two-array comparison analysis
generated detection call and change call for each probe set,
respectively. For duplicated control and treatment microarrays, each
probe set would possess four detection calls arisen from each
microarray, and four change calls produced by the orthogonal
comparisons between the control and treatment microarrays. The
fold change of a probe set was calculated based on the signal log ratios
resulted from two-array comparison analysis. The criteria of sig-
niﬁcantly differential expression for a probe set was: 1) it possessed at
least one “Present” detection call in the single-array analysis, 2) it
showed four consistent “Increase” or “Decrease” change calls (100%
standard) or three consistent “Increase” or “Decrease” change calls
plus one “No change” call (75% standard) in the two-array comparison
analysis, and 3) the magnitude of fold change was more than 1.2.
The genes differentially expressed in at least one of the three doses
of BPDE treatment were subjected to Cluster 3.0 software (Stanford
University) for hierarchical cluster analysis using Pearson correlation
(uncentered) distance metrics and average linkage cluster method.
The cluster result was visualized with Java TreeView 1.0.13 software
(Stanford University). Gene Set Enrichment Analysis (GSEA) was used
to analyze the functional categories enrichment in the differentially
expressed genes by comparing to the mSigDB gene ontology gene set
collection (v2.5) (http://www.broad.mit.edu/gsea/msigdb/index.jsp)
[48]. Individual gene sets were ﬁltered out when enough of the
members (by default 15–500 genes) were contained in the differen-
tially expressed gene list. The enrichment degree of a ﬁlter-out gene
set was denoted by the ratio relative to the gene set original size.
Quantitative real-time RT-PCR
Triplicate RNA samples were independently prepared for quanti-
tative real-time RT-PCR analysis. Total RNA was isolated with Trizol
reagents (Invitrogen), and all RNA samples were DNase-treated using
the DNA-free™ Kit (Ambion, Austin, TX) to eliminate DNA contam-
ination. RNA integrity was veriﬁed by 1% agarose gel electrophoresis
and the quantity was determined by spectrophotometry. Single-
strand cDNA was synthesized using the High-Capacity cDNA Archive
Kit (Applied Biosystems, Foster City, CA). Quantitative real-time RT-
PCR was performed using ABI TaqMan Low Density Arrays, which is a
384-well microﬂuidic card pre-loaded with optimised probes and
matching primers for customer-selected genes. The reaction system in
each well was about 2 μL, containing 1 ng cDNA template, 250 nM
probe, 900 nM each of the primers, and TaqMan® Universal PCR
Master Mix. The thermal cycling process was performed on an ABI
Prism 7900HT Sequence Detection System, starting with 50 °C for
2min and 94.5 °C for 10min, and continuingwith 40 cycles of 97 °C for
15 s and 59.7 °C for 30 s. Relative quantiﬁcation analysis was
performed with ABI Prism SDS 2.1.1 software. The endogenous control
18s rRNA was used to normalize differences in the input amount of
total cDNAs. Normalized ΔCt values were then used to determine the
statistical signiﬁcance (pb0.05) of differential expression between
341X. Lu et al. / Genomics 93 (2009) 332–342BPDE-exposed and control samples using Student's paired, two-tailed
t-test. Fold changes were calculated using the comparative CT method
as described in the ABI Prism 7900HT SDS User Guide.
Cell cycle analysis
Cells in 6-well plate were treated with various concentrations (0,
0.005, 0.05, 0.5 μM) of BPDE. At different times (4, 13 and 22 h) post
exposure, cells were harvested by trypsinization, ﬁxed in 70% ice-cold
ethanol at 4 °C for overnight, then washed and resuspended in PBS
containing propidium iodide (20 μg/mL), RNaseA (50 μg/mL), and
TritonX-100 (0.1%) at 37 °C for 30 min. Samples were then measured
on a Coulter EPICS XL ﬂow cytometer, and the post-acquisition list
mode data was analyzed with WinMDI 2.8 software.
Bioinformatic analysis
The PAP (Promoter Analysis Pipeline) web application suite (http://
bioinformatics.wustl.edu/webTools/portalModule/PromoterSearch.
do) was used to analyze the TFBSs (transcription factor binding sites)
in the promoter regions of the up-regulated genes [49]. It identiﬁes
speciﬁc TFBSs by calculating overrepresentation of characterized
transcription factor binding proﬁles in the promoter sequences
using weight matrices from TRANSFAC and JASPER databases. In
current study, the identiﬁed TFBSs (pb0.05) were reciprocally used for
determination of regulatory transcription factors for each gene.
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